Alimenté par : Claudia (ADFI Alsace), Gaëlle (ADFI), Isabelle, Maïlé Onfray
Cet outil s'appuie sur PubMind
Un accÚs direct à la littérature scientifique via la base PubMed permettant de faciliter la veille sur les enjeux complexes de la santé mentale et du fait religieux : de la neuroscience des croyances à l'étude des abus spirituels, en passant par la prise en charge des traumatismes et des processus de déconversion.
DerniĂšre synchronisation le 23/06/2026
J Surg Oncol . 2025;132 (5) :917-923
BACKGROUND AND OBJECTIVES: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant biliary tumor associated with a poor prognosis. Here, we explored conversion therapy (CT) for the treatment of locally advanced iCCA (LA-iCCA).METHODS: We retrospectively enrolled 115 patients with LA-iCCA at our single center from January 2019 to June 2024, with the final follow-up conducted in January 2025. The primary outcome measured was overall survival (OS), while the secondary outcome focused on progression-free survival (PFS). We utilized a propensity score matching (PSM) approach to adjust for potential confounders between the CT group and the systemic therapy (ST) group.RESULTS: Before PSM, the median OS was 34.57 months (95% CI: 19.22-49.91), while the median PFS was 17.30 months (95% CI: 12.89-21.71) in the CT group. Both OS and PFS were significantly longer than those in the ST group (both pâ